Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Entrectinib and Letrozole in Invasive Lobular Breast Carcinoma
NCT04551495Phase 2Active, not recruiting
- Sponsor
- Institut Jules Bordet
- Start
- Jan 2021
- Primary completion
- Jan 2025
- Modality
- Small Molecules
- Countries
- 2
01
Overview
A Phase 2 trial of entrectinib in invasive lobular carcinoma (ILC), sponsored by Institut Jules Bordet. Started Jan 2021; status: active, not recruiting.
02
Drugs
entrectinib
03
Conditions
invasive lobular carcinoma (ILC)
Beyond the preview
Go deeper on NCT04551495.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04551495.